Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab ; volume:14 ; number:6 ; day:16 ; month:10 ; year:2019 ; pages:647-656 ; date:12.2019
Targeted oncology ; 14, Heft 6 (16.10.2019), 647-656, 12.2019
- Creator
-
Kolberg, Hans-Christian
Colleoni, Marco
Santi, Patricia
Demetriou, Georgia Savva
Segui-Palmer, Miguel Angel
Fujiwara, Yasuhiro
Hurvitz, Sara A.
Hanes, Vladimir
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-019-00675-z
- URN
-
urn:nbn:de:101:1-2020032017520485515339
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kolberg, Hans-Christian
- Colleoni, Marco
- Santi, Patricia
- Demetriou, Georgia Savva
- Segui-Palmer, Miguel Angel
- Fujiwara, Yasuhiro
- Hurvitz, Sara A.
- Hanes, Vladimir
- SpringerLink (Online service)
Other Objects (12)
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties